Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01998035

Recruitment Status : Terminated (PI left institution)

First Posted : November 28, 2013

Last Update Posted : January 8, 2021

Sponsor:

Collaborator:

Celgene

Information provided by (Responsible Party):

Columbia University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	January 6, 2020
Actual Study Completion Date :	January 6, 2020
Certification/Extension First Submitted :	January 5, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada AM, Jacob AT, Kinahan C, Francescone M, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes DL, Scotto L, Sokol L, Shustov AR, O'Connor OA. Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study. Blood. 2020 Nov 10. pii: blood.2020009004. doi: 10.1182/blood.2020009004. [Epub ahead of print]

O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285.

To Top